Abstract

Survival outcomes for patients with lower grade gliomas (LrGG) continue to improve. However, damage caused both by tumor growth and by the consequences of treatment often leads to significantly impaired cognitive function and quality of life (QoL). While neuropsychological testing is not routine, serial clinical MRIs are standard of care for patients with LrGG. Thus, having a greater understanding of MRI indicators of cognitive and QoL impairment risk could be beneficial to patients and clinicians. In this work we sought to test the hypothesis that in clinically stable LrGG patients, T2 FLAIR hyperintensity volumes at the time of cognitive assessment are associated with impairments of cognitive function and QoL and could be used to help identify patients for cognitive and QoL assessments and interventions. We performed anatomical MR imaging, cognitive testing and QoL assessments cross-sectionally in 30 clinically stable grade 2 and 3 glioma patients with subjective cognitive concerns who were 6 or more months post-treatment. Larger post-surgical T2 FLAIR volume at testing was significantly associated with lower cognitive performance, while pre-surgical tumor volume was not. Older patients had lower cognitive performance than younger patients, even after accounting for normal age-related declines in performance. Patients with Astrocytoma, IDH mutant LrGGs were more likely to show lower cognitive performance than patients with Oligodendroglioma, IDH mutant 1p19q co-deleted LrGGs. Previous treatment with combined radiation and chemotherapy was associated with poorer self-reported QoL, including self-reported cognitive function. This study demonstrates the importance of appreciating that LrGG patients may experience impairments in cognitive function and QoL over their disease course, including during periods of otherwise sustained clinical stability. Imaging factors can be helpful in identifying vulnerable patients who would benefit from cognitive assessment and rehabilitation.

Highlights

  • Survival outcomes for patients with lower grade (WHO grade 2 and 3) gliomas (LrGG) continue to improve as diagnosis and treatment evolve, with current median survival of 5–15 years [1]

  • Complete cognitive function data were collected for 27 patients and complete quality of life (QoL) data were collected for 28, due to equipment errors

  • We identified imaging factors associated with lower cognitive function and QoL that may be useful when monitoring patients with these concerns

Read more

Summary

Introduction

Survival outcomes for patients with lower grade (WHO grade 2 and 3) gliomas (LrGG) continue to improve as diagnosis and treatment evolve, with current median survival of 5–15 years [1]. For patients with LrGG, tissue damage caused by tumor growth and by the consequences of treatment often leads to significantly impaired cognitive function [2,3,4,5,6,7]. These cognitive impairments frequently have a negative impact on patients’ QoL [8]. It is challenging for clinicians to anticipate the extent to which a patient’s cognition and QoL will be impacted The timing of these impairments over the disease course is unclear. Impairments that were present since diagnosis or surgery may only become apparent to patients as they complete treatment and begin to resume the trajectories of their “normal” lives, re-encountering challenges in work, home, or family life

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call